Panbela Therapeutics Beta
Cos'è Beta di Panbela Therapeutics?
Beta di Panbela Therapeutics Inc. è 1.27
Qual è la definizione di Beta?
BETA indica se una azione è più o meno volatile rispetto al mercato nel suo complesso. Un beta inferiore a 1 indica che la azione è meno volatile rispetto al mercato, mentre un beta più di 1 indica che la azione è più volatile. La volatilità è misurata come la fluttuazione del prezzo attorno alla media.
Beta is a measure of the risk arising from exposure to general market movements as opposed to idiosyncratic factors. The market portfolio of all investable assets has a beta of exactly 1. A beta below 1 can indicate either an investment with lower volatility than the market, or a volatile investment whose price movements are not highly correlated with the market. A beta greater than one generally means that the asset both is volatile and tends to move up and down with the market. Beta is important because it measures the risk of an investment that cannot be reduced by diversification. It does not measure the risk of an investment held on a stand-alone basis, but the amount of risk the investment adds to an already-diversified portfolio. In the capital asset pricing model, beta risk is the only kind of risk for which investors should receive an expected return higher than the risk-free rate of interest.
Beta di aziende nel Health Care settore su NASDAQ rispetto a Panbela Therapeutics
Cosa fa Panbela Therapeutics?
Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, together with its subsidiaries, focuses on developing disruptive therapeutics for the treatment of patients with cancer. The company focuses on diseases of the pancreas, including pancreatitis and pancreatic cancer, as well as neoadjuvant pancreatic cancer, colorectal cancer, ovarian cancer, and other agents in other cancer indications. Its lead product candidate is SBP-101, which is in Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.
Aziende con beta simili a Panbela Therapeutics
- Golden Valley Mines ha Beta di 1.27
- Sotera Health Co ha Beta di 1.27
- Tribune Publishing ha Beta di 1.27
- Plutus PowerGen Plc ha Beta di 1.27
- Lennar ha Beta di 1.27
- Intu Properties Plc ha Beta di 1.27
- Panbela Therapeutics ha Beta di 1.27
- Hollywood Bowl Plc ha Beta di 1.27
- S&T AG ha Beta di 1.27
- Synertec ha Beta di 1.27
- Hays plc ha Beta di 1.27
- Spark Power ha Beta di 1.27
- Office Properties Income Trust ha Beta di 1.27